Aurinia Pharmaceuticals INC Form 4 insider transactions

Aurinia Pharmaceuticals Inc. Director Craig A. Johnson acquired 23,931 stock options with an exercise price of $15.67, vesting one year from the grant date.

Aurinia Pharmaceuticals Inc. reports a stock option grant to Director Kathleen Goetz, with vesting details and exercise price.

Aurinia Pharmaceuticals Inc. reports a stock option grant to Director Tina Susan Nova, with vesting details and ownership information.

Aurinia Pharmaceuticals Director Jeffrey Allen Bailey acquired 23,931 stock options with an exercise price of $15.67.

CEO Kevin Tang and Tang Capital Management acquired over 814,000 shares of Aurinia Pharmaceuticals, signaling strong internal confidence in the company's value.

Chief Legal Officer Stephen P. Robertson was granted 115,541 performance stock units tied to future share price targets.

Aurinia Pharmaceuticals CFO Michael S. Hearne was granted 116,144 performance stock units and 70,230 stock options.

Aurinia Pharmaceuticals COO Ryan Cole was granted 116,144 performance stock units and 70,230 stock options.

Aurinia Pharmaceuticals Director Kevin Tang significantly increased his indirect beneficial ownership by purchasing nearly one million common shares across multiple transactions in late February and early March 2026.

Aurinia Pharmaceuticals' Chief Financial Officer, Joseph M. Miller, reported the acquisition of performance rights and employee stock options, alongside a disposition of shares to cover tax obligations.

Aurinia Pharmaceuticals CEO Peter Greenleaf reported the acquisition of performance rights and stock options, alongside a disposition of shares for tax obligations.

Aurinia Pharmaceuticals' Chief Operating Officer, Matthew Maxwell Donley, disposed of 32,901 common shares to cover tax withholding obligations.

Aurinia Pharmaceuticals CEO Peter Greenleaf reported the disposition of 100,171 common shares to cover tax obligations related to restricted stock unit vesting.

Aurinia Pharmaceuticals' CFO, Joseph M. Miller, reported a routine disposition of 32,424 common shares to cover tax obligations from restricted stock unit vesting.

Aurinia Pharmaceuticals' EVP, General Counsel Stephen P. Robertson, disposed of 34,638 common shares to cover tax withholdings related to restricted stock unit vesting.

Aurinia Pharmaceuticals' SVP, Chief Medical Officer, Greg Keenan, disposed of 11,552 common shares to cover tax withholding obligations related to restricted stock unit vesting.

Aurinia Pharmaceuticals' EVP, General Counsel Stephen P. Robertson reported an acquisition of shares from a performance award and a disposition for tax withholding, adjusting his beneficial ownership.

Aurinia Pharmaceuticals' Chief Operating Officer, Matthew Maxwell Donley, reported the acquisition of 54,166 common shares from a performance award and the disposition of 42,787 shares for tax withholding.

Aurinia Pharmaceuticals CFO Joseph M. Miller reported the acquisition of performance-based shares and subsequent tax-related dispositions, adjusting his beneficial ownership.

Aurinia Pharmaceuticals CEO Peter Greenleaf reported the acquisition of performance-based shares and the disposition of shares for tax withholding, alongside prior ESPP purchases.

Aurinia Pharmaceuticals Director Jeffrey Allen Bailey disposed of 2,716 common shares to cover tax obligations related to restricted stock unit vesting.

Aurinia Pharmaceuticals director Craig A. Johnson reported the disposition of 6,039 common shares to cover tax obligations from restricted stock unit vesting.

Aurinia Pharmaceuticals Inc. Director Kevin Tang significantly increased his indirect beneficial ownership through multiple common share purchases totaling 1.3 million shares.

Aurinia Pharmaceuticals' Chief Medical Officer, Greg Keenan, sold 20,000 shares of common stock for a weighted average price of $10.50 per share.

Director Tina Nova acquired stock options in Aurinia Pharmaceuticals, exercisable for 63,724 common shares at $8.15, vesting one year from the grant date.

Director Craig Johnson of Aurinia Pharmaceuticals Inc. was granted stock options on May 16, 2025, exercisable for 37,485 common shares.

Kathleen Goetz, a director of Aurinia Pharmaceuticals, was granted stock options to purchase 63,724 common shares on May 16, 2025, exercisable after one year.

Director Jeffrey Allen Bailey reports receiving a stock option grant from Aurinia Pharmaceuticals Inc.

Chief Medical Officer Greg Keenan sold 8,305 shares of Aurinia Pharmaceuticals Inc. to cover tax withholding obligations related to the vesting of restricted stock units.

Aurinia Pharmaceuticals' CEO, Peter Greenleaf, reports acquisition and disposal of company stock, including shares acquired through performance rights, employee share purchase plan, and sales to cover tax obligations.